|
1
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Khongkow P, Gomes AR, Gong C, Man EP,
Tsang JW, Zhao F, Monteiro LJ, Coombes RC, Medema RH, Khoo US, et
al: Paclitaxel targets FOXM1 to regulate KIF20A in mitotic
catastrophe and breast cancer paclitaxel resistance. Oncogene.
35:990–1002. 2016. View Article : Google Scholar
|
|
3
|
Borin TF, Angara K, Rashid MH, Achyut BR
and Arbab AS: Arachidonic acid metabolite as a novel therapeutic
target in breast cancer metastasis. Int J Mol Sci. 18:pii: E2661.
2017. View Article : Google Scholar
|
|
4
|
Arnold KM, Pohlig RT and Sims-Mourtada J:
Co-activation of Hedgehog and Wnt signaling pathways is associated
with poor outcomes in triple negative breast cancer. Oncol Lett.
14:5285–5292. 2017.PubMed/NCBI
|
|
5
|
McGuire A, Lowery AJ, Kell MR, Kerin MJ
and Sweeney KJ: Locoregional recurrence following breast cancer
surgery in the trastuzumab era: A systematic review by subtype. Ann
Surg Oncol. 24:3124–3132. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Gu G, Dustin D and Fuqua SA: Targeted
therapy for breast cancer and molecular mechanisms of resistance to
treatment. Curr Opin Pharmacol. 31:97–103. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Liu J, Xiao Y, Wei W, Guo JX, Liu YC,
Huang XH, Zhang RX, Wu YJ and Zhou J: Clinical efficacy of
administering oxaliplatin combined with S-1 in the treatment of
advanced triple-negative breast cancer. Exp Ther Med. 10:379–385.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Reaz S, Tamkus D and Andrechek ER: Using
gene expression data to direct breast cancer therapy: Evidence from
a preclinical trial. J Mol Med (Berl). 96:111–117. 2018. View Article : Google Scholar
|
|
9
|
Guo GC, Wang JX, Han ML, Zhang LP and Li
L: microRNA-761 induces aggressive phenotypes in triple-negative
breast cancer cells by repressing TRIM29 expression. Cell Oncol
(Dordr). 40:157–166. 2017. View Article : Google Scholar
|
|
10
|
Lam EW and Gomes AR: Forkhead box
transcription factors in cancer initiation, progression and
chemotherapeutic drug response. Front Oncol. 4:3052014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Abdeljaoued S, Bettaieb I, Nasri M, Adouni
O, Goucha A, El Amine O, Boussen H, Rahal K and Gamoudi A:
Overexpression of FOXM1 Is a Potential Prognostic Marker in Male
Breast Cancer. Oncol Res Treat. 40:167–172. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Lam AK, Ngan AW, Leung MH, Kwok DC, Liu
VW, Chan DW, Leung WY and Yao KM: FOXM1b, which is present at
elevated levels in cancer cells, has a greater transforming
potential than FOXM1c. Front Oncol. 3:112013.PubMed/NCBI
|
|
13
|
Hamurcu Z, Kahraman N, Ashour A and
Ozpolat B: FOXM1 transcriptionally regulates expression of integrin
β1 in triple-negative breast cancer. Breast Cancer Res Treat.
163:485–493. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Lee JJ, Lee HJ, Son BH, Kim SB, Ahn JH,
Ahn SD, Cho EY and Gong G: Expression of FOXM1 and related proteins
in breast cancer molecular subtypes. Int J Exp Pathol. 97:170–177.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Hamurcu Z, Ashour A, Kahraman N and
Ozpolat B: FOXM1 regulates expression of eukaryotic elongation
factor 2 kinase and promotes proliferation, invasion and
tumorgenesis of human triple negative breast cancer cells.
Oncotarget. 7:16619–16635. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) Method. Methods. 25:402–408. 2001.
View Article : Google Scholar
|
|
17
|
National Research Council (US) Institute
for Laboratory Animal Research: Guide for the Care and Use of
Laboratory Animals. National Academies Press (US); Washington, DC:
1996
|
|
18
|
Cancer Genome Atlas Network: Comprehensive
molecular portraits of human breast tumours. Nature. 490:61–70.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Xu Y, Li W, Liu X, Ma H, Tu Z and Dai Y:
Analysis of microRNA expression profile by small RNA sequencing in
Down syndrome fetuses. Int J Mol Med. 32:1115–1125. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Yang M, Li H, Li Y, Ruan Y and Quan C:
Identification of genes and pathways associated with MDR in
MCF-7/MDR breast cancer cells by RNA-seq analysis. Mol Med Rep.
17:6211–6226. 2018.PubMed/NCBI
|
|
21
|
Eisen MB, Spellman PT, Brown PO and
Botstein D: Cluster analysis and display of genome-wide expression
patterns. Proc Natl Acad Sci USA. 95:14863–14868. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Liu C, Chen N, Huang K, Jiang M, Liang H,
Sun Z, Tian J and Wang D: Identifying hub genes and potential
mechanisms associated with senescence in human annulus cells by
gene expression profiling and bioinformatics analysis. Mol Med Rep.
17:3465–3472. 2018.
|
|
23
|
Polak P, Karlić R, Koren A, Thurman R,
Sandstrom R, Lawrence M, Reynolds A, Rynes E, Vlahoviček K,
Stamatoyannopoulos JA, et al: Cell-of-origin chromatin organization
shapes the mutational landscape of cancer. Nature. 518:360–364.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Zona S, Bella L, Burton MJ, Nestal de
Moraes G and Lam EW: FOXM1: An emerging master regulator of DNA
damage response and genotoxic agent resistance. Biochim Biophys
Acta. 1839.1316–1322. 2014.
|
|
25
|
Sanders DA, Ross-Innes CS, Beraldi D,
Carroll JS and Balasubramanian S: Genome-wide mapping of FOXM1
binding reveals co-binding with estrogen receptor alpha in breast
cancer cells. Genome Biol. 14:R62013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Fischer M and Müller GA: Cell cycle
transcription control: DREAM/MuvB and RB-E2F complexes. Crit Rev
Biochem Mol Biol. 52:638–662. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Kwok JMM, Myatt SS, Marson CM, Coombes RC,
Constantinidou D and Lam EW: Thiostrepton selectively targets
breast cancer cells through inhibition of forkhead box M1
expression. Mol Cancer Ther. 7:2022–2032. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Yang N, Zhou TC, Lei XX, Wang C, Yan M,
Wang ZF, Liu W, Wang J, Ming KH, Wang BC, et al: Inhibition of
Sonic Hedgehog Signaling Pathway by Thiazole Antibiotic
Thiostrepton Attenuates the CD44+/CD24-Stem-Like Population and
Sphere-Forming Capacity in Triple-Negative Breast Cancer. Cell
Physiol Biochem. 38:1157–1170. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Chuang HY, Lee E, Liu YT, Lee D and Ideker
T: Network-based classification of breast cancer metastasis. Mol
Syst Biol. 3:1402007. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Chowdhury SA, Nibbe RK, Chance MR and
Koyutürk M: Subnetwork state functions define dysregulated
subnetworks in cancer. J Comput Biol. 18:263–281. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Szklarczyk D, Franceschini A, Wyder S,
Forslund K, Heller D, Huerta-Cepas J, Simonovic M, Roth A, Santos
A, Tsafou KP, et al: STRING v10: Protein-protein interaction
networks, integrated over the tree of life. Nucleic Acids Res.
43(D1): D447–D452. 2015. View Article : Google Scholar
|
|
32
|
Li L, Zhao F, Lu J, Li T, Yang H, Wu C and
Liu Y: Notch-1 signaling promotes the malignant features of human
breast cancer through NF-κB activation. PLoS One. 9:e959122014.
View Article : Google Scholar
|
|
33
|
Rizzo P, Miao H, D’Souza G, Osipo C, Song
LL, Yun J, Zhao H, Mascarenhas J, Wyatt D, Antico G, et al:
Cross-talk between notch and the estrogen receptor in breast cancer
suggests novel therapeutic approaches. Cancer Res. 68:5226–5235.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Wang Z, Li Y, Ahmad A, Banerjee S, Azmi
AS, Kong D, Wojewoda C, Miele L and Sarkar FH: Downregulation of
Notch-1 is associated with Akt and FoxM1 in inducing cell growth
inhibition and apoptosis in prostate cancer cells. J Cell Biochem.
112:78–88. 2011. View Article : Google Scholar
|
|
35
|
Christopoulos PF, Msaouel P and
Koutsilieris M: The role of the insulin-like growth factor-1 system
in breast cancer. Mol Cancer. 14:432015. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Suzuki S, Iwamoto M, Saito Y, Fuchimoto D,
Sembon S, Suzuki M, Mikawa S, Hashimoto M, Aoki Y, Najima Y, et al:
Il2rg gene-targeted severe combined immunodeficiency pigs. Cell
Stem Cell. 10:753–758. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Kopp S, Slumstrup L, Corydon TJ, Sahana J,
Aleshcheva G, Islam T, Magnusson NE, Wehland M, Bauer J, Infanger
M, et al: Identifications of novel mechanisms in breast cancer
cells involving duct-like multicellular spheroid formation after
exposure to the Random Positioning Machine. Sci Rep. 6:268872016.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Malin D, Kim IM, Boetticher E, Kalin TV,
Ramakrishna S, Meliton L, Ustiyan V, Zhu X and Kalinichenko VV:
Forkhead box F1 is essential for migration of mesenchymal cells and
directly induces integrin-beta3 expression. Mol Cell Biol.
27:2486–2498. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Xue J, Lin X, Chiu WT, Chen YH, Yu G, Liu
M, Feng XH, Sawaya R, Medema RH, Hung MC, et al: Sustained
activation of SMAD3/SMAD4 by FOXM1 promotes TGF-β-dependent cancer
metastasis. J Clin Invest. 124:564–579. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Arora R, Yates C, Gary BD, McClellan S,
Tan M, Xi Y, Reed E, Piazza GA, Owen LB and Dean-Colomb W:
Panepoxydone targets NF-kB and FOXM1 to inhibit proliferation,
induce apoptosis and reverse epithelial to mesenchymal transition
in breast cancer. PLoS One. 9:e983702014. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Li X, Roslan S, Johnstone CN, Wright JA,
Bracken CP, Anderson M, Bert AG, Selth LA, Anderson RL, Goodall GJ,
et al: MiR-200 can repress breast cancer metastasis through
ZEB1-independent but moesin-dependent pathways. Oncogene.
33:4077–4088. 2014. View Article : Google Scholar
|
|
42
|
Park MY, Kim KR, Park HS, Park BH, Choi
HN, Jang KY, Chung MJ, Kang MJ, Lee DG and Moon WS: Expression of
the serum response factor in hepatocellular carcinoma: Implications
for epithelial-mesenchymal transition. Int J Oncol. 31:1309–1315.
2007.PubMed/NCBI
|
|
43
|
Shankar J and Nabi IR: Correction: Actin
cytoskeleton regulation of epithelial mesenchymal transition in
metastatic cancer cells. PLoS One. 10:e01327592015. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Yang C, Chen H, Tan G, Gao W, Cheng L,
Jiang X, Yu L and Tan Y: FOXM1 promotes the epithelial to
mesenchymal transition by stimulating the transcription of Slug in
human breast cancer. Cancer Lett. 340:104–112. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Halasi M and Gartel AL: Targeting FOXM1 in
cancer. Biochem Pharmacol. 85:644–652. 2013. View Article : Google Scholar
|
|
46
|
Song X, Fiati Kenston SS, Zhao J, Yang D
and Gu Y: Roles of FoxM1 in cell regulation and breast cancer
targeting therapy. Med Oncol. 34:412017. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Ahn H, Sim J, Abdul R, Chung MS, Paik SS,
Oh YH, Park CK and Jang K: Increased expression of forkhead box M1
is associated with aggressive phenotype and poor prognosis in
estrogen receptor-positive breast cancer. J Korean Med Sci.
30:390–397. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Wierstra I: FOXM1 (Forkhead box M1) in
tumorigenesis: Overexpression in human cancer, implication in
tumorigenesis, oncogenic functions, tumor-suppressive properties,
and target of anticancer therapy. Adv Cancer Res. 119:191–419.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Bayraktar R, Ivan C, Bayraktar E,
Kanlikilicer P, Kabil NN, Kahraman N, Mokhlis HA, Karakas D,
Rodriguez-Aguayo C, Arslan A, et al: Dual Suppressive Effect of
miR-34a on the FOXM1/eEF2-Kinase Axis Regulates Triple-Negative
Breast Cancer Growth and Invasion. Clin Cancer Res. 24:4225–4241.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Yersal O and Barutca S: Biological
subtypes of breast cancer: Prognostic and therapeutic implications.
World J Clin Oncol. 5:412–424. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Krøigård AB, Larsen MJ, Thomassen M and
Kruse TA: Molecular concordance between primary breast cancer and
matched metastases. Breast J. 22:420–430. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Wierstra I and Alves J: FOXM1, a typical
proliferation-associated transcription factor. Biol Chem.
388:1257–1274. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Lv C, Zhao G, Sun X, Wang P, Xie N, Luo J
and Tong T: Acetylation of FOXM1 is essential for its
transactivation and tumor growth stimulation. Oncotarget.
7:60366–60382. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Kroemer G and Pouyssegur J: Tumor cell
metabolism: Cancer’s Achilles’ heel. Cancer Cell. 13:472–482. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Shang R, Pu M, Li Y and Wang D: FOXM1
regulates glycolysis in hepatocellular carcinoma by transactivating
glucose transporter 1 expression. Oncol Rep. 37:2261–2269. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Lei T and Ling X: IGF-1 promotes the
growth and metastasis of hepatocellular carcinoma via the
inhibition of proteasome-mediated cathepsin B degradation. World J
Gastroenterol. 21:10137–10149. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Hegde NS, Sanders DA, Rodriguez R and
Balasubramanian S: The transcription factor FOXM1 is a cellular
target of the natural product thiostrepton. Nat Chem. 3:725–731.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Rahman MA, Amin AR and Shin DM:
Chemopreventive potential of natural compounds in head and neck
cancer. Nutr Cancer. 62:973–987. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Tolcher AW, Peng W and Calvo E: Rational
Approaches for Combination Therapy Strategies Targeting the MAP
Kinase Pathway in Solid Tumors. Mol Cancer Ther. 17:3–16. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Yang N, Wang C, Wang Z, Zona S, Lin SX,
Wang X, Yan M, Zheng FM, Li SS, Xu B, et al: FOXM1 recruits nuclear
Aurora kinase A to participate in a positive feedback loop
essential for the self-renewal of breast cancer stem cells.
Oncogene. 36:3428–3440. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Ahmed M, Hussain AR, Siraj AK, Uddin S,
Al-Sanea N, Al-Dayel F, Al-Assiri M, Beg S and Al-Kuraya KS:
Co-targeting of Cyclooxygenase-2 and FoxM1 is a viable strategy in
inducing anticancer effects in colorectal cancer cells. Mol Cancer.
14:1312015. View Article : Google Scholar : PubMed/NCBI
|
